Advertisement

Topics

Switching From Preserved to Preserved-free Treatments for Glaucoma.

2014-08-27 04:00:29 | BioPortfolio

Summary

A 1-year prospective, randomized, investigator-masked trial comparing the confocal and clinical effects of treatment with unpreserved prostaglandins (tafluprost) versus preserved prostaglandins (latanoprost) in newly-diagnosed glaucoma patients.

Description

The study protocol comprises 5 visits: baseline, month 3, month 6, month 9, month 12.

At baseline a clinical evaluator will perform a complete ophthalmologic evaluation to confirm diagnosis. The following examinations will be done in the following sequence: anterior segment examination, Shirmer test, Break-up time test. Thereafter, a confocal evaluator will perform confocal microscopy of the central and the peripheral cornea. Finally, contact measurements will be done in the following order: IOP (which will be measured at 3 pm), pachimetry (only at baseline visit) and gonioscony (only at baseline visit). A 15 minutes interval will elapse between two consecutive tests.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Glaucoma

Intervention

Tafluprost, Latanoprost

Location

San Paolo Hospital
Milano
Italy
20142

Status

Recruiting

Source

University of Milan

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T04:00:29-0400

Clinical Trials [89 Associated Clinical Trials listed on BioPortfolio]

Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)

- Main objective is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both giv...

24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy

The study investigated the 24-hour efficacy and ocular surface health with preservative-free tafluprost and a combined preservative-free regimen (tafluprost and dorzolamide/timolol fixed c...

Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients

The aim of this work is to evaluate efficacy and tolerability of preservative containing 0.0015% tafluprost and preservative-free 0.0015% tafluprost. Both preservative containing and prese...

DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%

DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Tim...

Pharmacodynamics of Tafluprost 0.0015% Eye Drops: a Comparison Between the Preserved and Unpreserved Formulation

The objective of this study is to investigate the pharmacodynamics (as expressed in intraocular pressure [IOP]) of two formulations of tafluprost 0.0015% eyedrops (preserved and unpreserve...

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Latanoprost-induced Skin Depigmentation.

Latanoprost, and other prostaglandin analogs, have been previously associated with increased pigmentary reactions on the periocular skin. Here, we present a patient with paradoxical depigmentation of ...

Discovery, characterization, and clinical utility of prostaglandin agonists for the treatment of glaucoma.

Topical ophthalmic formulations of analogs of the endogenous arachidonic acid cyclooxygenase metabolite, prostaglandin F (PGF ), are the standard of care for treating the blinding disease glaucoma. Th...

Enantio- and Diastereoselective Synthesis of Latanoprost using an Organocatalyst.

An enantioselective total synthesis of Latanoprost was achieved. Its chiral cyclopentane core structure was constructed through an organocatalyst-mediated 3+2 cycloaddition reaction, and the chirality...

Switch from BAK-preserved to preservative-free latanoprost decreases anterior chamber flare in POAG patients.

To validate the hypothesis that BAK induces low-grade inflammation in the anterior chamber, we designed a study to investigate whether switching from BAK-preserved to preservative-free latanoprost in ...

Preperimetric Glaucoma Prospective Observational Study (PPGPS): Design, baseline characteristics, and therapeutic effect of tafluprost in preperimetric glaucoma eye.

There is no consensus on the diagnosis or treatment policy for Preperimetric Glaucoma (PPG) because the pathogenesis of PPG is not clear at this time. Preperimetric Glaucoma Prospective Observational ...

Medical and Biotech [MESH] Definitions

A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

A localized defect in the visual field bordered by an area of normal vision. This occurs with a variety of EYE DISEASES (e.g., RETINAL DISEASES and GLAUCOMA); OPTIC NERVE DISEASES, and other conditions.

A form of GLAUCOMA in which chronic optic nerve damage and loss of vision normally attributable to buildup of intraocular pressure occurs despite prevailing conditions of normal intraocular pressure.

More From BioPortfolio on "Switching From Preserved to Preserved-free Treatments for Glaucoma."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Searches Linking to this Trial